@phdthesis{oai:nagasaki-u.repo.nii.ac.jp:00026555,
 author = {山川, 智弘},
 month = {},
 note = {While clonal heterogeneity has been demonstrated in most cancers, quantitative assessment of individual tumor clones has not been translated to inform clinical practice. A few methods have been developed to investigate the tumor clonality of adult T cell leukemia/lymphoma (ATLL), but currently there is no clinically translatable method available for quantifying individual tumor clones in ATLL patients. Here, we present a methodology to assess the tumor clonality of ATLL and quantify patient-specific tumor clones in a clinical setting. The methodology consists of three steps: (1) selective amplification of restriction fragments containing a human T cell leukemia virus type 1 (HTLV-1) integration site, (2) amplicon deep sequencing to estimate the clonal structure and identify HTLV-1 integration sites of dominant clones, and (3) digital PCR targeting the HTLV-1 integration sites of the dominant clones to quantify specific tumor clones. We successfully tracked individual tumor clones using this approach and demonstrated that each clone had a distinct response to therapies. The procedure is straightforward and clinically feasible, which should facilitate the proper assessment and management of ATLL., 長崎大学学位論文 学位記番号:博(医歯薬)甲第1308号 学位授与年月日:令和3年3月3日, Author: Tomohiro Yamakawa, Naoki Uno, Daisuke Sasaki, Norihito Kaku, Kei Sakamoto, Kosuke Kosai, Hiroo Hasegawa, Yasushi Miyazaki and Katsunori Yanagihara, Citation: Molecular Therapy - Methods & Clinical Development, 19, pp.467-473; 2020, Nagasaki University (長崎大学), 博士(医学) (2021-03-03)},
 school = {Nagasaki University (長崎大学)},
 title = {A methodology for assessing tumor clonality of adult T-cell leukemia/lymphoma},
 year = {2020}
}